{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:54:38Z","timestamp":1762509278895,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.7759\/cureus.92967","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:54:44Z","timestamp":1758585284000},"source":"Crossref","is-referenced-by-count":1,"title":["Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report"],"prefix":"10.7759","author":[{"given":"Chelsea D","family":"Morinishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramee","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.035","article-title":"Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis","volume":"27","author":"Muthu V","year":"2021","unstructured":"Muthu V, Agarwal R, Dhooria S, Sehgal IS, Prasad KT, Aggarwal AN, Chakrabarti A. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect. 2021, 27:538-49. 10.1016\/j.cmi.2020.12.035","journal-title":"Clin Microbiol Infect"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1268840","article-title":"The outcome and the risk factors of mucormycosis among patients with hematological diseases: a systematic and meta-analysis","volume":"10","author":"Shen M","year":"2023","unstructured":"Shen M, Wang J, Lei M, Wang Z. The outcome and the risk factors of mucormycosis among patients with hematological diseases: a systematic and meta-analysis. Front Med (Lausanne). 2023, 10:1268840. 10.3389\/fmed.2023.1268840","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)","volume":"54","author":"Walsh TJ","year":"2012","unstructured":"Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012, 54:S55-60. 10.1093\/cid\/cir868","journal-title":"Clin Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103115","article-title":"The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis","volume":"81","author":"Brown L","year":"2025","unstructured":"Brown L, Tschiderer L, Alanio A, et al.. The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis. EClinicalMedicine. 2025, 81:103115. 10.1016\/j.eclinm.2025.103115","journal-title":"EClinicalMedicine"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mmcr.2019.12.005","article-title":"Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature","volume":"27","author":"Fehr M","year":"2020","unstructured":"Fehr M, Cathomas G, Graber A, Makert E, Gaus E, Boggian K. Multi-fungal sepsis and mucormycosis of the central nervous system in a patient treated with ibrutinib, a case report and review of the literature. Med Mycol Case Rep. 2020, 27:14-6. 10.1016\/j.mmcr.2019.12.005","journal-title":"Med Mycol Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/20499361241241199","article-title":"Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature","volume":"11","author":"Nguyen TM","year":"2024","unstructured":"Nguyen TM, Amenta E, Chapman L, Yellapragada S, Krishnan B, Lim J, Hamill RJ. Ibrutinib-associated cutaneous mucormycosis due to an Apophysomyces species: report of a case and review of the literature. Ther Adv Infect Dis. 2024, 11:10.1177\/20499361241241199","journal-title":"Ther Adv Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01120","article-title":"Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib","volume":"24","author":"Sittig KR","year":"2021","unstructured":"Sittig KR, Laageide LG, Akhtar Z, Wall GC, Kumar SC. Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib. IDCases. 2021, 24:e01120. 10.1016\/j.idcr.2021.e01120","journal-title":"IDCases"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/jof7121058","article-title":"Invasive fungal infections and targeted therapies in hematological malignancies","volume":"7","author":"Little JS","year":"2021","unstructured":"Little JS, Weiss ZF, Hammond SP. Invasive fungal infections and targeted therapies in hematological malignancies. J Fungi (Basel). 2021, 7:1058. 10.3390\/jof7121058","journal-title":"J Fungi (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8812528","article-title":"Fatal mucormycosis and aspergillosis in an atypical host: what do we know about mixed invasive mold infections?","volume":"2020","author":"Tsikala-Vafea M","year":"2020","unstructured":"Tsikala-Vafea M, Cao W, Olszewski AJ, Donahue JE, Farmakiotis D. Fatal mucormycosis and aspergillosis in an atypical host: what do we know about mixed invasive mold infections?. Case Rep Infect Dis. 2020, 2020:8812528. 10.1155\/2020\/8812528","journal-title":"Case Rep Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.729","article-title":"Pulmonary and cutaneous mucormycosis in high-risk chronic lymphocytic leukemia","volume":"166","author":"Ravi S","year":"2024","unstructured":"Ravi S, Ravi S, Miranda C, Dyal N. Pulmonary and cutaneous mucormycosis in high-risk chronic lymphocytic leukemia. Chest. 2024, 166:A1110-11. 10.1016\/j.chest.2024.06.729","journal-title":"Chest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2120-2","article-title":"Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia","volume":"94","author":"Tse E","year":"2015","unstructured":"Tse E, Leung RY, Kwong YL. Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. Ann Hematol. 2015, 94:165-7. 10.1007\/s00277-014-2120-2","journal-title":"Ann Hematol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2018.063","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs","volume":"10","author":"Facchinelli D","year":"2018","unstructured":"Facchinelli D, Marchesini G, Nadali G, Pagano L. Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs. Mediterr J Hematol Infect Dis. 2018, 10:e2018063. 10.4084\/MJHID.2018.063","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz AD","year":"2017","unstructured":"Zelenetz AD, Barrientos JC, Brown JR, et al.. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017, 18:297-311. 10.1016\/S1470-2045(16)30671-4","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123179","article-title":"Risk of serious adverse events, infection and sepsis in patients with relapsed and refractory chronic lymphocytic leukemia\/ small lymphocytic lymphoma treated with idelalisib","volume":"134","author":"Kopel J","year":"2019","unstructured":"Kopel J, Swarup S, Sultan A, et al.. Risk of serious adverse events, infection and sepsis in patients with relapsed and refractory chronic lymphocytic leukemia\/ small lymphocytic lymphoma treated with idelalisib. Blood. 2019, 134:5489. 10.1182\/blood-2019-123179","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones JA","year":"2017","unstructured":"Jones JA, Robak T, Brown JR, et al.. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017, 4:e114-26. 10.1016\/S2352-3026(17)30019-4","journal-title":"Lancet Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.05.006","article-title":"Infections in patients with chronic lymphocytic leukemia","volume":"45","author":"Guarana M","year":"2023","unstructured":"Guarana M, Nucci M. Infections in patients with chronic lymphocytic leukemia. Hematol Transfus Cell Ther. 2023, 45:387-93. 10.1016\/j.htct.2023.05.006","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely OA","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, et al.. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019, 19:e405-21. 10.1016\/S1473-3099(19)30312-3","journal-title":"Lancet Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56160","article-title":"Diagnosis of mucormycosis using frozen section, histopathology, culture, and reverse transcriptase polymerase chain reaction (RT-PCR) techniques: a comparative study","volume":"16","author":"Kiruthiga KG","year":"2024","unstructured":"Kiruthiga KG, Kulkarni A, Joshi A, Pradhan A, Naik S. Diagnosis of mucormycosis using frozen section, histopathology, culture, and reverse transcriptase polymerase chain reaction (RT-PCR) techniques: a comparative study. Cureus. 2024, 16:e56160. 10.7759\/cureus.56160","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21918","article-title":"Utility of intraoperative frozen sections in surgical decision making for acute invasive fungal rhinosinusitis","volume":"7","author":"Papagiannopoulos P","year":"2017","unstructured":"Papagiannopoulos P, Lin DM, Al-Khudari S, et al.. Utility of intraoperative frozen sections in surgical decision making for acute invasive fungal rhinosinusitis. Int Forum Allergy Rhinol. 2017, 7:502-7. 10.1002\/alr.21918","journal-title":"Int Forum Allergy Rhinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0696-OA","article-title":"Accuracy of intraoperative frozen section in detection of acute invasive fungal rhinosinusitis","volume":"145","author":"Alkhateb R","year":"2021","unstructured":"Alkhateb R, Menon PD, Tariq H, Hackman S, Nazarullah A, Mais DD. Accuracy of intraoperative frozen section in detection of acute invasive fungal rhinosinusitis. Arch Pathol Lab Med. 2021, 145:736-43. 10.5858\/arpa.2019-0696-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: a review of 929 reported cases","volume":"41","author":"Roden MM","year":"2005","unstructured":"Roden MM, Zaoutis TE, Buchanan WL, et al.. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005, 41:634-53. 10.1086\/432579","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-023-00463-3","article-title":"Novel approaches in the management of mucormycosis","volume":"17","author":"Lamoth F","year":"2023","unstructured":"Lamoth F. Novel approaches in the management of mucormycosis. Curr Fungal Infect Rep. 2023, 17:98-107. 10.1007\/s12281-023-00463-3","journal-title":"Curr Fungal Infect Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens DL","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al.. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014, 59:147-59. 10.1093\/cid\/ciu296","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2022.101332","article-title":"Combination therapy in mucormycosis: current evidence from the world literature, a mini review","volume":"33","author":"Meena DS","year":"2023","unstructured":"Meena DS, Kumar D, Bohra GK. Combination therapy in mucormycosis: current evidence from the world literature, a mini review. J Mycol Med. 2023, 33:101332. 10.1016\/j.mycmed.2022.101332","journal-title":"J Mycol Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed C","year":"2008","unstructured":"Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008, 47:364-71. 10.1086\/589857","journal-title":"Clin Infect Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: why, what, and how?","volume":"54","author":"Spellberg B","year":"2012","unstructured":"Spellberg B, Ibrahim A, Roilides E, et al.. Combination therapy for mucormycosis: why, what, and how?. Clin Infect Dis. 2012, 54:S73-8. 10.1093\/cid\/cir885","journal-title":"Clin Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12222","article-title":"Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies","volume":"57","author":"Abidi MZ","year":"2014","unstructured":"Abidi MZ, Sohail MR, Cummins N, et al.. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses. 2014, 57:687-98. 10.1111\/myc.12222","journal-title":"Mycoses"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis A","year":"2016","unstructured":"Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect. 2016, 22:811.e1-8. 10.1016\/j.cmi.2016.03.029","journal-title":"Clin Microbiol Infect"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.869","article-title":"824. Combination antifungal therapy for invasive mucormycosis in immunocompromised hosts: a single-center experience","volume":"10","author":"Lu B","year":"2023","unstructured":"Lu B, Ha DR, Shen S, et al.. 824. Combination antifungal therapy for invasive mucormycosis in immunocompromised hosts: a single-center experience. Open Forum Infect Dis. 2023, 10:ofad500.869. 10.1093\/ofid\/ofad500.869","journal-title":"Open Forum Infect Dis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab233","article-title":"Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis","volume":"76","author":"Gebremariam T","year":"2021","unstructured":"Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021, 76:2636-9. 10.1093\/jac\/dkab233","journal-title":"J Antimicrob Chemother"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.11.021","article-title":"A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India","volume":"26","author":"Patel A","year":"2020","unstructured":"Patel A, Kaur H, Xess I, et al.. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020, 26:944.e9-15. 10.1016\/j.cmi.2019.11.021","journal-title":"Clin Microbiol Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387160-invasive-cutaneous-mucormycosis-in-a-patient-with-chronic-lymphocytic-leukemia-on-obinutuzumab-idelalisib-and-bruton-tyrosine-kinase-degrader-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:54:45Z","timestamp":1758585285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387160-invasive-cutaneous-mucormycosis-in-a-patient-with-chronic-lymphocytic-leukemia-on-obinutuzumab-idelalisib-and-bruton-tyrosine-kinase-degrader-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.92967","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}